SVB Leerink Equities Analysts Decrease Earnings Estimates for Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
SVB Leerink Equities Analysts Decrease Earnings Estimates for Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) – SVB Leerink reduced their Q3 2022 EPS estimates for Turning Point Therapeutics in a research report issued to clients and investors on Monday, August 8th. SVB Leerink analyst A. Berens now anticipates that the company will earn ($2.19) per share for the quarter, down from their previous estimate of ($1.78). SVB Leerink has a "Market Perform" rating and a $76.00 price objective on the stock. The consensus estimate for Turning Point Therapeutics' current full-year earnings is ($6.85) per share. SVB Leerink also issued estimates for Turning Point Therapeutics' Q4 2022 earnings at ($2.24) EPS, FY2022 earnings at ($8.42) EPS, FY2023 earnings at ($9.38) EPS, FY2024 earnings at ($5.84) EPS, FY2025 earnings at $1.56 EPS and FY2026 earnings at $12.31 EPS.
Turning Point治療公司(納斯達克代碼：TPTX-GET評級)-SVB Leerink在8月8日星期一發布給客户和投資者的一份研究報告中下調了他們對Turning Point治療公司2022年第三季度每股收益的估計。SVB Leerink分析師A.Berens現在預計，該公司本季度每股收益為2.19美元，低於此前預測的1.78美元。SVB Leerink給予該股“市場表現”的評級和76.00美元的目標價。對Turning Point Treateutics目前全年收益的普遍估計為每股6.85美元。SVB Leerink還發布了對Turning Point Treeutics 2022財年第四季度每股收益(2.24美元)、2022財年每股收益(8.42美元)、2023財年每股收益(9.38美元)、2024財年每股收益(5.84美元)、2025財年每股收益1.56美元和2026財年每股收益12.31美元的預期。
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last issued its earnings results on Monday, August 8th. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($0.78). The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $2.27 million. During the same quarter in the prior year, the firm earned ($1.14) EPS. The company's revenue for the quarter was down 97.7% compared to the same quarter last year.
Turning Point Treateutics(納斯達克：多倫多證券交易所股票代碼：GET)最近一次發佈收益報告是在8月8日星期一。該公司公佈本季度每股收益(2.48美元)，低於(1.70美元)和(0.78美元)的普遍預期。該業務本季度的收入為12萬美元，而普遍預期為227萬美元。去年同一季度，該公司每股收益為1.14美元。與去年同期相比，該公司本季度的收入下降了97.7%。
Turning Point Therapeutics Price Performance
轉折點治療性價比
Shares of NASDAQ TPTX opened at $75.00 on Thursday. Turning Point Therapeutics has a 12-month low of $23.77 and a 12-month high of $82.20. The company has a market capitalization of $3.72 billion, a PE ratio of -10.87 and a beta of -0.18. The firm's 50-day moving average is $74.94 and its two-hundred day moving average is $46.41.
週四，納斯達克TPTX的股價開盤報75.00美元。Turning Point Treeutics的12個月低點為23.77美元，12個月高位為82.20美元。該公司市值為37.2億美元，市盈率為-10.87，貝塔係數為-0.18。該公司50日移動均線切入位在74.94美元，200日移動均線切入位在46.41美元。
Insider Activity at Turning Point Therapeutics
轉折點治療公司的內部活動
In related news, CFO Paolo Tombesi sold 1,183 shares of the company's stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total transaction of $88,654.02. Following the transaction, the chief financial officer now owns 28,700 shares of the company's stock, valued at $2,150,778. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.60% of the company's stock.
在相關新聞中，首席財務官保羅·湯貝西在7月27日星期三的一筆交易中出售了1,183股該公司股票。這些股票的平均價格為74.94美元，總成交金額為88,654.02美元。交易完成後，這位首席財務官現在持有該公司28,700股股票，價值2,150,778美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份法律文件中披露的，可以通過這個鏈接訪問。內部人士持有該公司8.60%的股份。
Hedge Funds Weigh In On Turning Point Therapeutics
對衝基金參與轉折點治療
A number of large investors have recently bought and sold shares of TPTX. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Turning Point Therapeutics by 35.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,692 shares of the company's stock worth $319,000 after purchasing an additional 1,744 shares during the period. DekaBank Deutsche Girozentrale raised its stake in Turning Point Therapeutics by 2.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 16,870 shares of the company's stock worth $789,000 after purchasing an additional 400 shares during the period. Duality Advisers LP purchased a new position in Turning Point Therapeutics during the fourth quarter worth approximately $1,451,000. Nisa Investment Advisors LLC raised its stake in Turning Point Therapeutics by 489.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,850 shares of the company's stock worth $516,000 after purchasing an additional 11,500 shares during the period. Finally, Virginia Retirement Systems ET AL raised its stake in Turning Point Therapeutics by 5.4% during the fourth quarter. Virginia Retirement Systems ET AL now owns 11,700 shares of the company's stock worth $558,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 90.33% of the company's stock.
一些大型投資者最近買賣了TPTX的股票。蘇黎世廣東銀行在第四季度將其在Turning Point Treeutics的持股增加了35.2%。Zurcher Kantonalbank蘇黎世廣東銀行在此期間又購買了1,744股，現在持有該公司6,692股股票，價值319,000美元。DekaBank Deutsche Girozentale在第四季度將其在Turning Point Treeutics的股份增加了2.4%。在此期間，德意志銀行又購買了400股，現在持有16,870股該公司股票，價值78.9萬美元。Duality Advisers LP在第四季度購買了Turning Point Treeutics的一個新頭寸，價值約1,451,000美元。NISA Investment Advisors LLC在第四季度將其在Turning Point Treateutics的持股增加了489.4%。NISA Investment Advisors LLC現在擁有13,850股該公司股票，價值516,000美元，在此期間又購買了11,500股。最後，弗吉尼亞退休系統等公司在第四季度將其在Turning Point Treateutics的股份增加了5.4%。弗吉尼亞退休系統等公司現在擁有11,700股該公司的股票，價值55.8萬美元，在此期間又購買了600股。對衝基金和其他機構投資者持有該公司90.33%的股票。
About Turning Point Therapeutics
關於轉折點療法
(Get Rating)
(獲取評級)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治療公司是一家臨牀階段的精確腫瘤學生物製藥公司，致力於設計和開發針對癌症遺傳驅動因素的治療方法。它開發了一系列酪氨酸激酶抑制劑(TKI)，針對TKI-NAI、̈Ve和TKI預治療患者的癌症基因驅動因素。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免費獲取StockNews.com關於轉折點治療(TPTX)的研究報告
- 霍尼韋爾看好穩定和多元化的股票
- 為什麼要投資高收益股利股票？
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
- 清潔能源法案通過後，太陽能股大放異彩
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《轉折點治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Turning Point Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。